Psychedelics are transforming the way we understand depression and its treatment – Robin Carhart-Harris

While we suspected that psilocybin might perform well compared to the SSRI, we had not expected it to perform as well as it did. In fact, the initial main hypothesis for this trial was that the psilocybin therapy would have superior effects on psychological wellbeing, but not on depression severity scores. This prediction was generally supported, but people in the psilocybin group also showed evidence of greater improvements across most depression measures, as well as anxiety symptoms, work and social functioning, suicidal feelings and the ability to feel emotion and pleasure.

Ketamine Explained, The Next Big Antidepressant | The War on Drugs

Can LSD and psilocybin provide relief to people suffering from difficult-to-treat conditions such as depression and anxiety? Robin Carhart-Harris is a neuroscientist and head of the Imperial Centre for Psychedelic Research, which builds on over a decade of pioneering work psychedelic research, including a clinical trial that has kick-started global efforts to develop psilocybin therapy into a licensed treatment for depression.

Ketamine for Unipolar and Bipolar Depression

Due to unmet clinical needs for efficient drugs with a rapid onset of antidepressant effects, we aimed to evaluate the efficacy of single-dose ketamine in different subgroups of patients with major depression and establish whether repeated ketamine administration could be a viable strategy to maintain treatment gains.

Scroll to Top